Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.57 |
| ▸ | HPGD | P15428 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | GAA | P10253 | 6/20 | 0.57 |
| ▸ | GLA | P06280 | 5/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | STAT6 | P42226 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220072 | 0.88 | KDM4E (0.58) | KDM4EHPGDALDH1A1GAAGLA | |
| SCHEMBL9379333 | 0.86 | KDM4E (0.56) | KDM4EHPGDALDH1A1GAAGLA | |
| SCHEMBL17808847 | 0.82 | KDM4E (0.60) | KDM4EHPGDALDH1A1GAAGLA | |
| SCHEMBL10473124 | 0.82 | KDM4E (0.59) | KDM4EHPGDALDH1A1GAAGLA | |
| SCHEMBL13313505 | 0.81 | KDM4E (0.54) | KDM4EHPGDALDH1A1GAAGLA | |
| SCHEMBL17802254 | 0.80 | KDM4E (0.53) | KDM4EHPGDALDH1A1GAAGLA | |
| SCHEMBL21577471 | 0.80 | KDM4E (0.58) | KDM4EHPGDALDH1A1GAAGLA | |
| SCHEMBL17808807 | 0.80 | TP53 (0.56) | KDM4EHPGDALDH1A1GAAGLA | |
| SCHEMBL10473037 | 0.79 | KDM4E (0.47) | KDM4EHPGDALDH1A1GAAGLA | |
| SCHEMBL13313510 | 0.79 | CHEK1 (0.49) | KDM4EHPGDALDH1A1GAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227292-B1 | 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS | ALTERITY THERAPEUTICS LTD (AU) | 2022-03-09 | — | — | EP | disclosed |
| US-20210230159-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2021-07-29 | — | — | US | disclosed |
| US-11008319-B2 | 4H-pyrido[1,2-a]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2021-05-18 | — | — | US | disclosed |
| CN-111961050-A | 4H-pyrido [1,2-a ] pyrimidin-4-one compounds | 普拉纳生物技术有限公司 | 2020-11-20 | — | — | CN | disclosed |
| US-20200317670-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2020-10-08 | — | — | US | disclosed |
| CN-107001360-B | 4H-pyrido [1,2-a ] pyrimidin-4-one compounds | 普拉纳生物技术有限公司 | 2020-09-18 | — | — | CN | disclosed |
| US-10738050-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190352301-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2019-11-21 | — | — | US | disclosed |
| US-10287285-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2019-05-14 | — | — | US | disclosed |
| US-20170267676-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| WO-2007147217-A1 | METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR | PRANA BIOTECHNOLOGY LIMITED (AU) | 2007-12-27 | — | — | WO | disclosed |
| EP-1652839-A2 | Drug efflux pump inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1227084-B1 | DRUG DISCHARGE PUMP INHIBITORS | TRINE PHARMACEUTICALS INC (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1227084-A1 | DRUG DISCHARGE PUMP INHIBITORS | Microcide Pharmaceuticals, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738050-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | KDM4E 2827/4885HPGD 292/4885ALDH1A1 299/4885 |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | MGMT, DHFR, IDH2 | KDM4E 2823/4885HPGD 107/4885ALDH1A1 1278/4885 |
| US-20200317670-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | KDM4E 2827/4885HPGD 292/4885ALDH1A1 299/4885 |
| US-10287285-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | KDM4E 2827/4885HPGD 292/4885ALDH1A1 299/4885 |
| US-11008319-B2 | 4H-pyrido[1,2-a]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | KDM4E 2827/4885HPGD 292/4885ALDH1A1 299/4885 |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | ACHE, PSEN1, PSEN2 | KDM4E 3329/4885HPGD 1135/4885ALDH1A1 703/4885 |
| US-20190352301-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | KDM4E 2827/4885HPGD 292/4885ALDH1A1 299/4885 |
| US-20210230159-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | KDM4E 2827/4885HPGD 292/4885ALDH1A1 299/4885 |
| US-20170267676-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | KDM4E 2827/4885HPGD 292/4885ALDH1A1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.